公开(公告)号：US20140180245A1

公开(公告)日：2014-06-26

申请号：US14113803

申请日：2012-04-25

申请人： Vernon G. Wong ,  Tan Pham ,  William S. White ,  Glenn T. Huang ,  Mae W. Hu

发明人： Vernon G. Wong ,  Tan Pham ,  William S. White ,  Glenn T. Huang ,  Mae W. Hu

IPC分类号： A61M5/315

CPC分类号： A61M5/31536 ,  A61M5/315 ,  A61M5/3156 ,  A61M5/31591

摘要： Devices that guide the accurate loading and dispensing of predetermined doses of fluid from injection syringes are disclosed.

摘要翻译： 公开了引导从注射器精确加载和分配预定剂量的流体的装置。

公开(公告)号：US10022502B2

公开(公告)日：2018-07-17

申请号：US14113803

申请日：2012-04-25

申请人： Vernon G. Wong ,  Tan Pham ,  William S. White ,  Glenn T. Huang ,  Mae W. Hu

发明人： Vernon G. Wong ,  Tan Pham ,  William S. White ,  Glenn T. Huang ,  Mae W. Hu

IPC分类号： A61M5/315

摘要： Devices that guide the accurate loading and dispensing of predetermined doses of fluid from injection syringes are disclosed.

公开(公告)号：US20140213646A1

公开(公告)日：2014-07-31

申请号：US14168139

申请日：2014-01-30

申请人： Vernon G. Wong ,  Mae W. Hu ,  Glenn T. Huang

发明人： Vernon G. Wong ,  Mae W. Hu ,  Glenn T. Huang

IPC分类号： A61K31/216

CPC分类号： A61K31/5575 ,  A61K9/0019 ,  A61K9/0048 ,  A61K47/14

摘要： The present embodiments provide for methods of treating elevated intraocular pressure or glaucoma using a sustained release medicament consisting of prostaglandin in benzyl benzoate that is injected intraocularly no more frequently than once every two months.

摘要翻译： 本实施例提供了使用由前列腺素组成的持续释放药物治疗眼内压或青光眼的方法，所述缓释药物由苯甲酸苄酯组成，其眼内注射的频率不得超过每两个月一次。

公开(公告)号：US09814773B2

公开(公告)日：2017-11-14

申请号：US14124631

申请日：2012-06-11

申请人： Vernon G. Wong ,  Louis L. Wood ,  Carol Wood ,  Glenn T. Huang

发明人： Vernon G. Wong ,  Louis L. Wood ,  Glenn T. Huang

IPC分类号： A61K39/395 ,  A61K9/00 ,  A61K47/14 ,  A61K47/20 ,  A61K47/34 ,  A61K38/17 ,  A61K9/08

CPC分类号： A61K39/39541 ,  A61K9/0024 ,  A61K9/0051 ,  A61K9/08 ,  A61K38/1709 ,  A61K47/14 ,  A61K47/20 ,  A61K47/34

摘要： The present invention provides for injectable pharmaceutical sustained release formulations for delivery of active agents, particularly therapeutic proteins, to the eye. The formulations are biocompatible, biodegradable sustained release formulations comprising low-solubility liquid excipients and relatively small amounts (less than about 10%) of biocompatible, biodegradable polymer such as PLA or PLGA polymers. A unit dose of 5 μL to 100 μL of the formulation provides for sustained release of the agent for at least 14 days.

公开(公告)号：US20140140992A1

公开(公告)日：2014-05-22

申请号：US14124631

申请日：2012-06-11

申请人： Vernon G. Wong ,  Louis L. Wood ,  Glenn T. Huang

发明人： Vernon G. Wong ,  Louis L. Wood ,  Glenn T. Huang

IPC分类号： A61K47/34 ,  A61K39/395 ,  A61K38/17

CPC分类号： A61K39/39541 ,  A61K9/0024 ,  A61K9/0051 ,  A61K9/08 ,  A61K38/1709 ,  A61K47/14 ,  A61K47/20 ,  A61K47/34

摘要： The present invention provides for injectable pharmaceutical sustained release formulations for delivery of active agents, particularly therapeutic proteins, to the eye. The formulations are biocompatible, biodegradable sustained release formulations comprising low-solubility liquid excipients and relatively small amounts (less than about 10%) of biocompatible, biodegradable polymer such as PLA or PLGA polymers. A unit dose of 5 μL to 100 μL of the formulation provides for sustained release of the agent for at least 14 days.

摘要翻译： 本发明提供了用于将活性剂特别是治疗性蛋白质递送至眼睛的可注射药物缓释制剂。 制剂是包含低溶解度液体赋形剂和相对少量（小于约10％）生物相容性，可生物降解的聚合物如PLA或PLGA聚合物的生物相容性，可生物降解的持续释放制剂。 单位剂量为5μL至100μL的制剂可使药剂持续释放至少14天。

公开(公告)号：US08962009B2

公开(公告)日：2015-02-24

申请号：US13840535

申请日：2013-03-15

申请人： Glenn T. Huang ,  Thierry Nivaggioli

发明人： Glenn T. Huang ,  Thierry Nivaggioli

IPC分类号： A61F2/14 ,  A61K9/00 ,  A61K31/573 ,  A61K45/06 ,  A61K31/58

CPC分类号： A61K9/0051 ,  A61K9/0092 ,  A61K31/573 ,  A61K31/58 ,  A61K45/06 ,  A61K2300/00

摘要： Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.

摘要翻译： 生物相容性眼内植入物包括彼此相关的类固醇和聚合物，以促进类固醇进入眼睛大于约两个月的时间。 类固醇可以与可生物降解的聚合物基质相关联，例如两种可生物降解聚合物的基质。 或者，类固醇可以与具有一个或多个开口有效以允许类固醇释放到外部环境中的聚合物涂层相关联。 植入物可以放置在眼睛中以治疗一种或多种眼睛状况。 类固醇从植入物中释放超过约两个月，可能会释放超过几年。

公开(公告)号：US08440216B2

公开(公告)日：2013-05-14

申请号：US13613636

申请日：2012-09-13

申请人： Glenn T. Huang ,  Thierry Nivaggioli

发明人： Glenn T. Huang ,  Thierry Nivaggioli

IPC分类号： A61F2/14

CPC分类号： A61K9/0051 ,  A61K9/0092 ,  A61K31/573 ,  A61K31/58 ,  A61K45/06 ,  A61K2300/00

摘要： Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.

公开(公告)号：US20080131485A1

公开(公告)日：2008-06-05

申请号：US11927613

申请日：2007-10-29

申请人： Glenn T. Huang ,  James Burke ,  Patrick M. Hughes ,  Kai-Ming Zhang ,  Ton Lin ,  Larry A. Wheeler ,  Rosy Sheng Donn

发明人： Glenn T. Huang ,  James Burke ,  Patrick M. Hughes ,  Kai-Ming Zhang ,  Ton Lin ,  Larry A. Wheeler ,  Rosy Sheng Donn

IPC分类号： A61K9/00 ,  A61K31/498

CPC分类号： A61K31/498 ,  A61K9/0051 ,  A61K47/34

摘要： Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.

公开(公告)号：US20130236525A1

公开(公告)日：2013-09-12

申请号：US13840535

申请日：2013-03-15

申请人： Glenn T. Huang ,  Thierry Nivaggioli

发明人： Glenn T. Huang ,  Thierry Nivaggioli

IPC分类号： A61K9/00 ,  A61K31/58

CPC分类号： A61K9/0051 ,  A61K9/0092 ,  A61K31/573 ,  A61K31/58 ,  A61K45/06 ,  A61K2300/00

摘要： Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.

公开(公告)号：US20130017244A1

公开(公告)日：2013-01-17

申请号：US13613636

申请日：2012-09-13

申请人： Glenn T. Huang ,  Thïerry Nivaggioli

发明人： Glenn T. Huang ,  Thïerry Nivaggioli

IPC分类号： A61K9/00 ,  A61P27/02 ,  A61K31/56

CPC分类号： A61K9/0051 ,  A61K9/0092 ,  A61K31/573 ,  A61K31/58 ,  A61K45/06 ,  A61K2300/00

摘要： Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.